References
- Reid D M, Kennedy N SS, Smith M A, Tothill P, Nuki G. Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid therapy. Br Med J 1982; 285: 330–2
- Frijlink W B, Bijvoet O LM, Te Velde J, Heynen G. Treatment of Paget's disease with (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD). Lancet 1979; 1: 799–803
- Mautalen C A. Treatment of Paget's bone disease with the bisphosphonate APD. Henry Ford Hosp Med J 1983; 21: 244–8
- Miravet L, Kuntz D. L'amino-hydroxy-propylidenebisphosphonate le traitment de maladies de Paget resistantes a la calcitonine et/on 1'etidronate. Rev Rheum Mal Osteoartic 1989; 56: 287–92
- Elte J WF, Bijvoet O LM, Cleton F J, van Oosteron A T, Sleebom H P. Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol 1986; 22: 493–500
- Man Z, Otero A B, Rendo P, Barazzutti L, Sánchez J, Avalos C. Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 1990; 335: 663
- Zanchetta J R, Bogado C R. Effects of pamidronate treatment on biochemical markers of bone turnover in postmenopausal osteoporosis. J Bone Miner Res 1992; 7(S2)196
- Fromm G A, Vega E, Plantalech L, Galich A M, Mautalen C A. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporosis Int 1991; 1: 129–33
- Spivacow F R, Roldán E JA, del Valle E E, Rodriguez G, Rey P, Insúa A, et al. Tolerance of pamidronate (APD) soft capsules in 755 patients. Bone Miner 1992; 17(S1)19
- Ralston S H, Hacking L, Willocks L, Bruce F, Pitkeathly D A. Clinical, biochemical, and radiogtaphic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 396–9
- Tan P LJ, Ames R, Yeoman S, Ibbertson H K, Caughey D E. Effects of amino bisphosphonates infusion on biochemical indices of bone metabolism in rheumatoid arthritis. Br J Rheumatol 1989; 28: 325–8
- Bijvoet O LM, Frijlink W B, Jie K, van der Linden H, Meijer C JLM, Mulder H, et al. APD in Paget' s disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum 1980; 23: 1193–204
- Mautalen C A, Casco C A, González D, Ghiringhelli G R, Massironi C, Fromm G A, et al. Side effects of disodium aminohydroxypropylidene diphosphonate (APD) during treatment of bone disease. Br Med J 1984; 288: 828
- Genant H K. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 1983; 75: 35–47
- Eggelmeijer F, Papapoulos S E, Valkema R, Hermans J, Landman J O, Pauwels E KJ, et al. Double blind placebo controlled trial of continuous oral pamidronate in rheumatoid arthritis: effects on bone mass after 1 year. Bone Miner 1992; 17(S1)31